22UA:ETR
BioNTech SE - ADR
€80.55
arrow_upward
+0.94%(+0.75) 1D
Oct 15, 5:35:58 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 22UA...
Open
€79.40
High
€80.80
Low
€78.75
Mkt. cap
22.66B
Avg. vol.
26.31K
Volume
15.60K
52-wk high
€105.70
52-wk low
€68.30
No. of employees
8K
Open
€79.40
High
€80.80
Low
€78.75
Mkt. cap
22.66B
Avg. vol.
26.31K
Volume
15.60K
52-wk high
€105.70
52-wk low
€68.30
No. of employees
8K
News stories
From web sources and news partners
ad-hoc-news.de
·
4 hours ago
Canaccord cuts target for BioNTech stock to USD 132.00
ad-hoc-news.de
·
9 hours ago
BioNTech's Pipeline Reckoning: BNT113 Stumble and Insider Sales Keep the Stock 25% Below Its Peak
Pluang
·
1 day ago
BioNTech shares drop 7.13% after trial failure raises concerns over oncology program claims
Simply Wall Street
·
1 day ago
BioNTech Stock Faces Questions After Cancer Trial Missed Progression Free Survival Goal
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR